Boehringer Ingelheim

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Tuesday, August 29, 2017

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

[Read More]

Boehringer Ingelheim releases phase III praxbind study results

Wednesday, July 12, 2017

Boehringer Ingelheim announced final results from RE-VERSE AD. The study shows that idarucizumab, marketed in the U.S. as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations. The effects were consistent both in patients requiring an urgent surgery or intervention, and in patients presenting with uncontrollable or life-threatening bleeding. The reversal of the anticoagulant effect of Pradaxa allowed physicians to quickly initiate necessary emergency interventions. The findings were presented at the International Society on Thrombosis and Haemostasis (ISTH) 26th Biennial Congress in Berlin, Germany and simultaneously published in the New England Journal of Medicine.

[Read More]

Agilis Biotherapeutics expands Commercial, Medical Teams

Tuesday, May 9, 2017

Agilis Biotherapeutics, a biotechnology company advancing innovative gene therapy products for the treatment of rare genetic diseases that affect the central nervous system (CNS), has expanded its commercial and medical teams, hiring Markus Peters, Ph.D., as chief commercial officer; Kirsten Gruis, M.D., as chief medical officer; and Anne Marie Conway, M.H.A, R.N., as vice president, Clinical Operations.

[Read More]

The continued exploration of modernizing clinical trials

Monday, May 1, 2017

The need for an alternative to the paper-based clinical trial process is long overdue. Not only is the original method cost- and labor-intensive, but it can delay new drug development, as well. The first siteless technology model for clinical trial research was introduced last year, and since then studies in this area continue.

[Read More]

FDA grants Orphan designation to Boehringer Ingelheim’s BI 836858 for myelodysplastic syndromes

Thursday, March 9, 2017

Boehringer Ingelheim has announced that the FDA has granted Orphan Drug designation to its anti-CD33 monoclonal antibody BI 836858 for the treatment of myelodysplastic syndromes (MDS). Orphan Drug designation is granted by the FDA to investigational compounds intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people.

[Read More]

Novo Nordisk, Servier, Otsuka, Teva among top sponsors

Wednesday, March 1, 2017

Sponsors have done a good job of maintaining, but not improving, the overall quality of their relationships with investigative sites during the past two years, according to a new CenterWatch survey, but performance gaps have widened across several of the attributes sites identify as the most important for conducting a successful study.

[Read More]